Actively Recruiting
Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer
Led by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated on 2025-07-11
200
Participants Needed
2
Research Sites
274 weeks
Total Duration
On this page
Sponsors
L
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
B
Bayer
Collaborating Sponsor
AI-Summary
What this Trial Is About
After a patient is diagnosed with colon cancer, they receive a CT of the chest, abdomen, and pelvis to see if the cancer has spread (metastasized) to other parts of the body. A common site for the cancer to spread to is the liver. If an abnormality is seen in the liver on CT, sometimes an MRI of the liver is required to determine a) whether it is cancer or not and b) whether there are small tumours in the liver that were not visible on CT. During the MRI, the patient is injected with intravenous (IV) contrast. This makes liver lesions more conspicuous and also helps determine if they are cancerous or not. The most commonly used IV contrast agent is called Gadovist. However, there is another IV contrast agent called Primovist that is better at detecting liver metastases from colon cancer than Gadovist. This is very important information for surgeons, because if they considering cutting out (resecting) the liver tumours, they want to make sure they get them all. Unfortunately, Primovist is used sparingly in Canadian hospitals because it is more expensive than Gadovist and the MRI takes longer. Some early small studies have suggested that it may be possible to shorten the Primovist MRI significantly (e.g. from 60 minutes to 15 minutes), making it economically feasible to offer Primovist to more patients. However, there have not been any large studies performed to confirm these findings. The purpose of this study is to compare the accuracy of colon cancer liver metastasis detection between a regular, full-length Primovist MRI versus a shortened Primovist MRI protocol. The economic impact will also be assessed.
CONDITIONS
Official Title
Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years of age or older
- Biopsy-proven diagnosis of colorectal cancer
- Prior imaging showing liver lesions that may be metastases
- Signed and dated informed consent provided
- Willingness to follow study procedures and be available for the study duration
- Able to tolerate MRI required by the study protocol
You will not qualify if you...
- Implanted medical device or metal object incompatible with MRI
- Baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2
- Severe claustrophobia not relieved by oral medication
- History of severe allergic reaction to gadolinium-based contrast agents
- Weight exceeding MRI table limits
- Pregnancy
- Diffuse, definitively unresectable liver metastases
- Severe liver dysfunction classified as ALBI grade 3
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
St. Joseph's Healthcare
London, Ontario, Canada, N6A 4V2
Actively Recruiting
2
London Health Sciences Centre
London, Ontario, Canada, N6A5A5
Actively Recruiting
Research Team
H
Harry Marshall, MD/PhD
CONTACT
Z
Zahra Kassam, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here